Kane Biotech (TSE:KNE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech has gained attention with a new publication in Pathogens journal and multiple conference presentations, highlighting the potential of their enzyme DispersinB® as a broad-spectrum antibiofilm agent. The company’s ongoing research efforts are showcased through presentations on the antibiofilm properties of revyve™ Antimicrobial Wound Gel Spray, signalling a commitment to advancing biofilm science and developing effective treatments for chronic wound infections.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.